AstraZeneca (NASDAQ:AZN) on Monday night received accelerated approval from the U.S. Food and Drug Administration (FDA) for its lung cancer drug Datroway. The approval covers use in patients with EGFR ...

AstraZeneca targets $80bn revenue by 2030, ... AstraZeneca: Fascinating Company With Lofty Ambitions - Just Not A Buy Yet. Jun. 07, 2025 4:55 AM ET AstraZeneca PLC (AZN) ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic ...

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

AstraZeneca has signed a deal worth up to $5.2bn to work with a Chinese biotech company using AI to develop new treatments for chronic diseases.

The pharmaceutical company AstraZeneca has filed a federal lawsuit against Utah Attorney General Derek Brown and Utah Insurance Commissioner Jon Pike over a recent law that is intended to allow ...

At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, ... At cancer meetings, the cookies the company hands out at its booths are almost as famous as its drugs.

AstraZeneca, the global pharmaceutical company that generated more than $54 billion in revenue in 2024, is now suing Utah Attorney General Derek Brown and Utah Insurance Commissioner Jon Pike to ...

AstraZeneca (AZ) has announced that a wider range of chronic kidney disease (CKD) patients across England and Wales will be able to access Forxiga (dapagliflozin), following updated final draft ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the European Commission (EC) to treat chronic lymphocytic leukaemia (CLL) in the ...